Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
FOSTER CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be participating in the following upcoming investor conferences in March.
TD Cowen's 46th Annual Health Care Conference
Format: Fireside Chat
Date and Time: Monday, March 2, 2026 at 3:50 p.m. ET
Location: Boston, MA
Leerink Global Healthcare Conference
Format: Fireside Chat
Date and Time: Monday, March 9, 2026 at 1:40 p.m. ET
Location: Miami, FL
Barclays 28th Annual Global Healthcare Conference
Format: 1x1 Meetings
Date: Tuesday, March 10, 2026
Location: Miami, FL
The Citizens Life Sciences Conference
Format: Fireside Chat
Date and Time: Wednesday, March 11, 2026 at 9:00 a.m. ET
Location: Miami, FL
Live webcasts of the fireside chats will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcasts will be archived on Terns’ website for at least 30 days following the presentations.
About Terns Pharmaceuticals
Terns Pharmaceuticals is a clinical-stage oncology company reimagining known biology to deliver high impact medicines. Our lead program TERN-701 is a highly selective, allosteric BCR-ABL inhibitor with a potentially best-in-disease profile that could meaningfully improve upon the efficacy, safety and convenience of existing treatments for CML. For more information, please visit: www.ternspharma.com.
Contacts for Terns
Investors
Justin Ng
investors@ternspharma.com
Media
Jenna Urban
CG Life
media@ternspharma.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
